系统性红斑狼疮1000例临床研究  

Clinical Study of 1000 Patients with Systemic Lupus Erythematosus.

作　　者：姜学义[1] 峰下哲[2] 杨学莉[1] 杨杰[1] 韩春雷[1] 王黎曼 

机构地区：[1]北京医科大学第三临床医学院皮肤科,100083 [2]日本东京医科齿科大学难治疾患研究所

出　　处：《中国皮肤性病学杂志》1993年第2期76-79,共4页The Chinese Journal of Dermatovenereology

摘　　要：本文对1962年至1992年诊治的1000例系统性红斑狼疮患者的临床资料进行分析。探讨了本病常见的诱发因素、临床表现、早期诊断及治疗与预后的关系。资料表明,32.6%的患者查无明显诱因,病情极易复发,伴严重内脏损害,预后不佳。在临床中,蛋白丢失性肠病的发生率为11.2%,应予以重视。患者3年、5年、10年、20年和30年的生存率分别为95.9%、93.5%、87.6%、66.6%和60.9%。近十年来,采用定期免疫学监测、中西医结合治疗、纤溶联合疗法治疗难治性狼疮肾炎等措施,使本病预后得以明显改善。Clinical data of 1000 patients with systemic lupus erythematosus(SLE)at our department from 1962 to 1992 was analysed. Inducing factors,clinical features, early diagnosis, treatment, and prognosis were dis cussed. It showed that 32.6% of the patients could't be found out definite inducing factor,patients of this group had higher incidence of relapse, major organ involvement and worse prognosis. 11.2% of the patients suffered from protien—losing enteropathy clinically. In 802 SLE cases, 3 years, 5 years, 10 years, 20 years and 30 years survival rates were 95.9% ,93.5%, 87.6%,66. 7%and 60.9% .respectively. The prognosis of SLE had improved within the last ten years,as the result of regular immunologic test. the combination of Chinese with Western Medicine and treated refratory lupus nephritis with eombinative fibrinolysis-threapy.

关 键 词：红斑狼疮 免疫测定 肠疾病 

分 类 号：R593.241[医药卫生—内科学]